Tice Bcg Powder, For Suspension
NDC Package 0052-0602-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Tice Bcg (bacillus calmette-guerin) powders is tICE® BCG is indicated for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder, and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). This formulation utilizes a powder, for suspension delivery system. Marketed by Merck Sharp & Dohme Llc, this product is identified by NDC 0052-0602 and is authorized under FDA application BLA102821.

Identification & Billing

NDC Package Code
0052-0602-02
Package Description
1 VIAL in 1 CARTON / 50 mL in 1 VIAL (0052-0602-01)
Product Code
0052-0602
11-Digit Billing Format
00052060202
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 1653484 - BCG, Tice strain 50 MG Powder for Intravesical Suspension
  • RxCUI: 1653484 - BCG, live, Tice strain 50 MG Powder for Intravesical Suspension
  • RxCUI: 213744 - Tice BCG 50 MG Powder for Intravesical Suspension
  • RxCUI: 213744 - BCG, live, Tice strain 50 MG Powder for Intravesical Suspension [Tice BCG]

Clinical Specifications

Proprietary Name
Tice Bcg
Non-Proprietary Name
Bacillus Calmette-guerin
Substance Name
Bacillus Calmette-guerin Substrain Tice Live Antigen
Dosage Form
Powder, For Suspension - An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a suspension (a liquid preparation containing the solid particles dispersed in the liquid vehicle).
Administration Route
Intravesical - Administration within the bladder.
Active Ingredient(s)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN 50 mg/50mL
Pharmacologic Class
Usage Information
TICE® BCG is indicated for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder, and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence.TICE BCG is not indicated for papillary tumors of stages higher than T1.

Regulatory & Marketing

Labeler Name
Merck Sharp & Dohme Llc
Product Type
Human Prescription Drug
FDA Application #
BLA102821
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
08-24-1990
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J9030
Source: ASP
Bcg live intravesical 1mg
HCPCS Dosage 1 MG
Units / Pkg 50

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0052-0602-02 identifies a specific commercial package of 1 vial in 1 carton / 50 ml in 1 vial (0052-0602-01) of Tice Bcg, a human prescription drug labeled by Merck Sharp & Dohme Llc. This powder, for suspension is formulated for intravesical use and contains bacillus calmette-guerin substrain tice live antigen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merck Sharp & Dohme Llc on August 24, 1990. The current certification is valid through December 31, 2027.

How is this Merck Sharp & Dohme Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00052060202. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0052-0602-02
11-Digit CMS (5-4-2)
00052-0602-02

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.